Commit To Buy Mineralys Therapeutics At $22.50, Earn 16.1% Annualized Using Options

Mineralys Therapeutics (MLYS) is trading at $37.05 and a June 2026 $22.50 put can be sold for a $1.70 premium, implying a $20.80 cost basis if assigned and a 16.1% annualized return from premium collection. Assignment would require a 39.4% decline from current levels; the stock's trailing twelve‑month volatility is 97%, underscoring high price variability. The trade offers income but limits upside exposure to the premium while leaving substantial downside risk if shares fall into assignment.

Analysis

Market structure: High IV (trailing ~97%) and a $1.70 premium on a June‑2026 $22.50 MLYS put (current stock $37.05) makes option sellers and broker-dealers short-term winners by harvesting a 16.1% annualized yield, while long equity holders and late buyers face outsized downside if a binary biotech event hits. The bilateral nature of exchange‑cleared options limits counterparty risk but concentrates assignment/dilution risk on shareholders if a clinical/regulatory shock forces financing.

Risk assessment: Tail scenarios include a failed trial or FDA action that could gap MLYS down >50–80% or trigger an emergency financing (dilution risk) — a low-probability but portfolio‑breaking event for naked put sellers. Near-term (days–weeks) IV can spike on news; short/medium term (months to June 2026) assignment/dilution risk dominates; long term depends on cash runway and product milestones.

Trade implications: If you want shares, only sell the June‑2026 $22.50 cash‑secured put sized to a max 1–2% net exposure and only if willing to own at $20.80; otherwise prefer defined‑risk bearish/options plays (put spreads or long straddles around known catalysts). Allocate sector hedges (e.g., short IBB or buy IBB puts) if you have concentrated small‑cap biotech exposure; avoid naked short positions sized above 2% of NAV.

Contrarian angles: The market may underprice the chance of dilutive financings — implied compensation (16% annualized) is attractive only if realized vol < implied; with 97% realized, sellers are likely undercompensated for binary downside. Historical parallels: small biotech binary events regularly cause 50–90% moves; prefer defined‑risk structures rather than cash‑secured naked puts unless you intend to own long-term.

Key Decisions for Investors

• If willing to own MLYS, establish a cash‑secured June 2026 $22.50 put position sized to no more than 1% of portfolio (obl. to buy at $20.80), close or hedge if MLYS < $15 or IV increases +20 vol points from today.
• If bearish or volatility buyer, buy a defined‑risk put spread (long June 2026 $22.50 / short $15 puts) sized 0.5–1% NAV to protect vs >40% downside while capping cost; exit on clinical/regulatory news or if spread value doubles.
• If exposed to small‑cap biotech idiosyncratic risk, reduce net exposure to XBI/IBB‑like ETFs by 25–30% over 30 days and purchase IBB 3‑month 10% OTM puts as a 0.5% NAV hedge ahead of expected catalysts.
• Avoid selling long‑dated naked puts on MLYS >2% NAV unless IV drops below its 6‑month median (target IV rank <50%); instead harvest premium with monthly/quarterly short put rolls and strict assignment stop‑loss rules.
• Monitor MLYS filings and press releases daily for cash‑runway updates or trial readout dates over the next 90 days; halt additional put selling if company discloses financing needs or sets a pivotal readout within 60 days.